Corantes naturais de urucum - Emepa

GILMAN, G.A., HARDMAN,, J.G., LIMBIRD, L.E. As Bases Farmacológicas daTerapêutica, 10 a edição, Rio de Janeiro , Editora McGraw-Hill Interamericanado Brasil, 1.671p, 2003GOSSLAU, A., CHEN, K.Y. Nutraceuticals, apoptosis, and disease prevention.Nutrition, v. 20, n.1, p. 95-102, 2004.GREENWALD, P., CLIFFORD, C.K., MILNER, J.A. Diet and cancer prevention.European Journal of Cancer, v. 37, p.948-965, 2001.HOLLMAN, P.C.H., TRIJP, J.M.P., MENGELERS, M.J.B., VRIES, J.H.M.,KATAN, M.B. Bioavailability of the dietary antioxidant flavonol quercetin inman.Cancer Letters, v. 114, p. 139-140, 1997.IGURA, K., OHTA, T., KURODA, Y., KAJI, K. Reservatrol and quercetin inhibitangiogeness in vitro. Cancer letters. V. 171, p.11-16, 2001.KJELDSEN, E., SVEJSTRUP, J.Q., GROMOVA, H., ALSNER, J.,WESTERGAARD, O. Camptothecin inhibits both the clevage and religationreactions of eukaryotic DNA topoisomerase I. Journal of Molecular Biology, v.228, p. 1025-1030, 1992.KUTCHAN, T.M. Alkaloid biosynthesis; the basis for metabolic engineering ofmedicinal plants. Plant Cell, v.7, p. 1059-1070, 1995.LACO, G.S., COLLINS, J.R., LUKE, B.T.Human topoisomerase I inhibtion:docking camptothecin and derivates into a structure-based active site model.Biochemistry, v.41, p.1428-1435, 2002.LAMBERTS, J.D., YANG, C.S. Cancer chemopreventive activity andbioavailability of tea and tea polyphenols. Mutation Research, v. 523-524, p.201-208, 2003.LARSEN, A.K., ESCARGUEIL, A.E., SKLADANOWSKI, A. Catalytictopoisomerase II inhibitors in cancer therapy, Pharmacology & Therapeutics, v.99, p. 167-181, 2003.LAVERGNE, O. DEMARQUAY, D., KASPRZYK, P.G., BIGG,D.C.H.Homocamptothecins; E-ring modified CPT analogues. Ann New YorkAcad Sci, v. 922, p. 100-111, 2000.LEHNINGER, A.L., NELSON,D.L., COX, M.M. Princípios de Bioquímica. 3 aedição, São Paulo, Editora Sarvier, 2002.LI, T.K., LIU, L.F., tumor cell induced by topoisomease targeting drugs. AnnRev Pharmacol Toxicol, v. 41, p. 53-77, 2001.LICHTMAN, S.M., SKIRVIN, J.A., VEMULAPALLI, S.. Pharmacology ofantineoplastic agents in older câncer patients. Critical Reviews inOncology/Hematology, n.46, p.101-114, 2003.145